Edap Tms SA
Edap Tms SA develops and commercializes high-intensity focused ultrasound (HIFU) systems for non-invasive treatment of urological and gynecological conditions.
Business. Edap Tms SA (EDAP.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of medical products, with its primary listing on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Analyst recommendations
3 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Edap Tms SA (EDAP.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of medical products, with its primary listing on the NASDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Edap Tms SA has a market price of $4.13 and a market capitalization of $154.8 million, with a price-to-book ratio of 7.97 and a price-to-tangible-book ratio of 7.97. The company's liquidity position is characterized by $20.5 million in cash and equivalents, but it carries $24.6 million in long-term debt, resulting in a debt-to-equity ratio of 1.27 and a current ratio of 1.54. The company's negative operating cash flow of $16.4 million and free cash flow of $31.6 million indicate significant liquidity constraints.
The company's profitability metrics are weak, with a net loss of $29.2 million and an operating loss of $24.7 million in the latest period. Return on equity is -150.65%, and return on assets is -37.02%, both significantly below industry norms for medical equipment firms. Gross profit of $30.0 million on $70.5 million in revenue yields a 42.5% gross margin, but this is insufficient to offset operating expenses.
Edap Tms SA operates in a single business segment focused on HIFU systems, with no disclosed geographic revenue breakdown in the latest financials. The company's revenue concentration in a single product line and limited geographic diversification increases exposure to market-specific risks.
The company's growth trajectory is uncertain, with no revenue growth data provided in the latest financials. Analysts have issued a mean price target of $5.50 and a median price target of $4.00, with a mean recommendation of 2.67 (leaning toward hold). The absence of strong buy ratings and the presence of two hold recommendations suggest limited near-term upside.
The company faces medium liquidity risk due to negative net cash after subtracting total debt. Dilution risk is assessed as low, with no recent share issuance activity and no material dilution adjustments in the valuation model. The company's capital structure is highly leveraged, with total liabilities of $59.6 million against total equity of $19.4 million.
Recent filings and transcripts show no material changes in the company's strategic direction or product pipeline. The company continues to focus on expanding its HIFU technology in urology and gynecology markets, but faces competition from established medical device firms.
- Edap Tms SA is a high-risk, speculative play in the advanced medical equipment sector with a weak balance sheet and negative cash flows.
- The company's valuation is stretched relative to book value, with a price-to-book ratio of 7.97 despite significant operating losses.
- Analysts are divided on the stock, with a mean price target of $5.50 but no strong buy ratings.
- The company's reliance on a single product line and limited geographic diversification increases vulnerability to market shifts.
- Liquidity constraints and high debt levels pose ongoing operational risks.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,68 |
| Revenue | —no estimate | —no estimate | 67,7M USD |
| Operating income | —no estimate | —no estimate | -22,8M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Edap Tms SA Market data — financials · 2026-05-27
- Edap Tms SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -54.3%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 27.0%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 279.5%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -42.1%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -11.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -11.1%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 15.5%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -11.6%Derived (calculated)
- Net margin (FY 2025-12-31): -41.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 42.5%Derived (calculated)
- Return on equity (FY 2025-12-31): -150.7%Derived (calculated)
- Return on assets (FY 2025-12-31): -37.0%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.54xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 3.07xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -34.0%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): -0.3%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -41.8%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -41.8%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 4.4%Derived (calculated)
- Current liabilities (annual): USD 37.14MSEC XBRL filing
- Total liabilities (annual): USD 59.58MSEC XBRL filing
- Current assets (annual): USD 57.16MSEC XBRL filing
- Shares outstanding (annual): 37.48MSEC XBRL filing